PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects
Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …
death through malignancies among women in developed countries. Population …
[HTML][HTML] The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy
F Ardito, M Giuliani, D Perrone… - International …, 2017 - spandidos-publications.com
Protein phosphorylation is an important cellular regulatory mechanism as many enzymes
and receptors are activated/deactivated by phosphorylation and dephosphorylation events …
and receptors are activated/deactivated by phosphorylation and dephosphorylation events …
PI3K/AKT/mTOR-targeted therapy for breast cancer
K Zhu, Y Wu, P He, Y Fan, X Zhong, H Zheng, T Luo - Cells, 2022 - mdpi.com
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
Comprehensive molecular portraits of human breast tumours
Brigham & Women's Hospital & Harvard Medical … - Nature, 2012 - nature.com
We analysed primary breast cancers by genomic DNA copy number arrays, DNA
methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and …
methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and …
Sequence analysis of mutations and translocations across breast cancer subtypes
S Banerji, K Cibulskis, C Rangel-Escareno, KK Brown… - Nature, 2012 - nature.com
Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with
an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy …
an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy …
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh… - Cancer cell, 2014 - cell.com
Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast
cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A …
cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A …
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
Genomic findings underscore the heterogeneity of head and neck squamous cell carcinoma
(HNSCC). Identification of mutations that predict therapeutic response would be a major …
(HNSCC). Identification of mutations that predict therapeutic response would be a major …
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials
C Fritsch, A Huang, C Chatenay-Rivauday… - Molecular cancer …, 2014 - AACR
Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that
selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while …
selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while …
Cancer development, progression, and therapy: an epigenetic overview
S Sarkar, G Horn, K Moulton, A Oza, S Byler… - International journal of …, 2013 - mdpi.com
Carcinogenesis involves uncontrolled cell growth, which follows the activation of oncogenes
and/or the deactivation of tumor suppression genes. Metastasis requires down-regulation of …
and/or the deactivation of tumor suppression genes. Metastasis requires down-regulation of …
Drug resistance in colorectal cancer: from mechanism to clinic
Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …